IRS2 and neoplasm: Consistent with the in vitro experiments, HCT116IRS2 cells formed larger tumors and exhibited accelerated growth (by 304% 21 days after injection, P = 0.03) (Figure 2D), whereas, LS513sh-IRS2 cells showed decreased tumor outgrowth (by 247% 25 days after injection, P = 0.005) (Figure 2E).